# OnCo record nct07432295 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07432295/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07432295", "NCT07432295" ;
  schema:name "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)"@en ;
  schema:alternateName "GIVA-2"@en ;
  schema:description "A phase 2 trial of Nivolumab, FLOT, CAPOX in metastatic cancer, run by I-Mab Biopharma US Limited, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07432295/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07432295> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-02-11" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/flot/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/i-mab/> .